Tarsus Pharmaceuticals (TARS) Preferred Stock Liabilities (2019 - 2020)
Tarsus Pharmaceuticals' (TARS) quarterly Preferred Stock Liabilities came in at $103.2 million in Q3 2020, up 2794.47% year-on-year from $3.6 million in Q4 2019, and up 62.71% quarter-over-quarter from $63.4 million in Q2 2020.
Tarsus Pharmaceuticals (TARS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Tarsus Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $103.2 million for Q3 2020.
- On a quarterly basis, Preferred Stock Liabilities rose 2794.47% year-over-year to $103.2 million in Q3 2020; TTM through Sep 2020 was $103.2 million, a 2794.47% increase from a year earlier, with the FY2019 full-year figure at $63.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $103.2 million in Q3 2020 per TARS's latest filing, from $63.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $103.2 million in Q3 2020 and bottomed at $3.6 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tarsus Pharmaceuticals | 2.52 Bn | 2.41 Bn | 152.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 103.16 Mn |
| Jun 30, 2020 | 63.40 Mn |
| Mar 31, 2020 | 63.40 Mn |
| Dec 31, 2019 | 63.40 Mn |
| Sep 30, 2019 | 3.56 Mn |